Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Alkeon Capital Management LLC

Alkeon Capital Management LLC increased its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 13.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 633,845 shares of the biotechnology company's stock after acquiring an additional 75,000 shares during the period. Alkeon Capital Management LLC owned approximately 0.66% of Sarepta Therapeutics worth $79,161,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Fifth Third Wealth Advisors LLC acquired a new stake in Sarepta Therapeutics in the 2nd quarter valued at about $607,000. Teachers Retirement System of The State of Kentucky acquired a new stake in Sarepta Therapeutics in the second quarter valued at approximately $4,771,000. Simplify Asset Management Inc. lifted its stake in Sarepta Therapeutics by 84.6% in the third quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company's stock worth $24,105,000 after acquiring an additional 88,474 shares during the last quarter. Securian Asset Management Inc. acquired a new position in Sarepta Therapeutics during the 2nd quarter worth approximately $1,187,000. Finally, Natixis Advisors LLC purchased a new stake in shares of Sarepta Therapeutics in the 2nd quarter valued at approximately $1,918,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Barclays decreased their price objective on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an "overweight" rating for the company in a research report on Thursday, August 8th. William Blair raised Sarepta Therapeutics to a "strong-buy" rating in a research report on Friday, August 30th. Piper Sandler cut their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating on the stock in a research report on Wednesday. HC Wainwright initiated coverage on shares of Sarepta Therapeutics in a research note on Monday. They issued a "sell" rating and a $80.00 price objective for the company. Finally, Raymond James reaffirmed an "outperform" rating and issued a $150.00 target price on shares of Sarepta Therapeutics in a report on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $175.77.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock traded down $4.60 during mid-day trading on Friday, hitting $133.34. 777,534 shares of the company were exchanged, compared to its average volume of 1,246,366. Sarepta Therapeutics, Inc. has a 12-month low of $78.67 and a 12-month high of $173.25. The company has a market capitalization of $12.74 billion, a P/E ratio of 106.67 and a beta of 0.81. The business's 50 day simple moving average is $122.37 and its two-hundred day simple moving average is $131.48. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.